Q1 FY27 results: revenue up 5.9%, net loss narrows to Rs 75 million

Pat NegativeExceptional ItemEmphasis Of MatterResults View source PDF Explain this filing

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-7.4%Reaction day

₹233.26

prior close

₹234.26

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-7.7% vs market

Pharmaceuticals peers, median of 167sector-0.2%-7.2% vs sector

On the reaction day the stock moved 7.7 pts less than Nifty Microcap 250 and 7.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

-3.1

15m

-4.3

30m

-6.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-7.4+0.4-7.7-0.2-7.2

Next day

-3.1+0.4-3.5+0.4-3.5

-4.7+0.3-5.0+0.6-5.3

-6.5+0.2-6.7+0.7-7.2

-9.1+0.5-9.7+0.7-9.8

-7.0+0.7-7.7+1.0-8.0

-8.7+0.9-9.6-0.1-8.6

15d

-12.5+1.6-14.1+0.0-12.5

+4.0+2.4+1.6+2.3+1.7

-3.1+1.1-4.2+2.6-5.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 standalone revenue rose 5.9% YoY to Rs 4,028 million. Pharma segment grew 15% YoY while crop protection fell 4.7%. Net loss narrowed to Rs 75 million from Rs 227 million YoY, aided by Rs 89 million exceptional gain on gratuity reversal. EPS at minus 0.61. Auditor flagged pending Supreme Court matter on environmental compliance as emphasis of matter.

Likely market impact

Loss narrowed YoY but stock still in red; environmental case and USFDA warning letter remain overhangs on Pharma.